| Phenotype | Fish | Conditions | Figures | 
    
    
        
            | endothelial cell elnb expression decreased amount, abnormal | s843Tg/s843Tg + MO1-gata1a | standard conditions | Fig. 5
                    
                    from Facchinello et al., 2022 
 | 
    
        
            | endothelial cell elna expression decreased amount, abnormal | s843Tg/s843Tg + MO1-gata1a | standard conditions | Fig. 5
                    
                    from Facchinello et al., 2022 
 | 
    
        
            | intermediate cell mass of mesoderm drll.3 expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | intermediate cell mass of mesoderm drl expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | erythroid lineage cell slc4a1a expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | hematopoietic system drll.3 expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | intermediate cell mass of mesoderm drll.2 expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | blood island spi1b expression mislocalised, abnormal | AB + MO1-gata1a | standard conditions | Fig. 2  from Takeuchi et al., 2015 
 | 
    
        
            | intermediate cell mass of mesoderm drll.1 expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | hematopoietic system drll.2 expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | intermediate cell mass of mesoderm spi1b expression mislocalised, abnormal | AB + MO1-gata1a | standard conditions | Fig. 4  from Takeuchi et al., 2015 
 | 
    
        
            | intermediate cell mass of mesoderm spi1b expression increased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | intermediate cell mass of mesoderm slc4a1a expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | hematopoietic system drl expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | hematopoietic system drll.1 expression decreased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | monocyte lcp1 expression increased amount, abnormal | AB + MO1-gata1a | standard conditions | Fig. 6  from Pimtong et al., 2014 
 | 
    
        
            | caudal hematopoietic tissue blvra expression increased amount, abnormal | TL + MO1-gata1a | standard conditions | Fig. 6
                    
                    from Holowiecki et al., 2017 
 | 
    
        
            | liver blvrb expression increased amount, abnormal | TL + MO1-gata1a | standard conditions | Fig. 6
                    
                    from Holowiecki et al., 2017 
 | 
    
        
            | intermediate cell mass of mesoderm blvra expression decreased amount, abnormal | TL + MO1-gata1a | standard conditions | Fig. 6
                    
                    from Holowiecki et al., 2017 
 | 
    
        
            | intermediate cell mass of mesoderm blvrb expression absent, abnormal | TL + MO1-gata1a | standard conditions | Fig. 6
                    
                    from Holowiecki et al., 2017 
 | 
    
        
            | caudal hematopoietic tissue blvrb expression increased amount, abnormal | TL + MO1-gata1a | standard conditions | Fig. 6
                    
                    from Holowiecki et al., 2017 
 | 
    
        
            | heart blvrb expression increased amount, abnormal | TL + MO1-gata1a | standard conditions | Fig. 6
                    
                    from Holowiecki et al., 2017 
 | 
    
        
            | nucleate erythrocyte hbae1.1 expression increased distribution, abnormal | TU + MO1-gata1a | control | Fig. 5
                    
                    from Li et al., 2020 
 | 
    
        
            | blood circulating cell absent, abnormal | WT + MO1-gata1a | standard conditions | Fig. 2  from Vermot et al., 2009 
 | 
    
        
            | atrioventricular valve morphology, abnormal | WT + MO1-gata1a | standard conditions | Fig. 2  from Vermot et al., 2009 
 | 
    
        
            | whole organism foxc1b expression decreased amount, abnormal | WT + MO1-gata1a | control | Fig. 6  from Chen et al., 2017 
 | 
    
        
            | nucleate erythrocyte development disrupted, abnormal | WT + MO1-gata1a | standard conditions | Fig. 8  from Helker et al., 2013 
 | 
    
        
            | nucleate erythrocyte absent, abnormal | WT + MO1-gata1a | standard conditions | Fig. 8  from Helker et al., 2013 
 | 
    
        
            | common cardinal vein blood vessel endothelial cell decreased amount, abnormal | WT + MO1-gata1a | standard conditions | Fig. 8  from Helker et al., 2013 
 | 
    
        
            | myeloid cell increased amount, abnormal | WT + MO1-gata1a | standard conditions | Fig. S6  from Hall et al., 2007 
 | 
    
        
            | blood decreased viscosity, abnormal | WT + MO1-gata1a | standard conditions | Fig. 2  from Vermot et al., 2009 
 | 
    
        
            | whole organism foxc1a expression decreased amount, abnormal | WT + MO1-gata1a | control | Fig. 6  from Chen et al., 2017 
 | 
    
        
            | dorsal aorta foxc1b expression decreased amount, abnormal | hu10049Tg + MO1-gata1a | control | Fig. 6  from Chen et al., 2017 
 | 
    
        
            | whole organism foxc1b expression decreased amount, abnormal | hu10049Tg + MO1-gata1a | control | Fig. 6  from Chen et al., 2017 
 | 
    
        
            | cardiac ventricle EGFP expression increased amount, abnormal | ig11Tg + MO1-gata1a | control | Fig. 2  from Heckel et al., 2015 
 | 
    
        
            | endothelial cell jag1b expression decreased amount, abnormal | s843Tg + MO1-gata1a | control | Fig. 4  from Chen et al., 2017 
 | 
    
        
            | endothelial cell hey1 expression decreased amount, abnormal | s843Tg + MO1-gata1a | control | Fig. 4  from Chen et al., 2017 
 | 
    
        
            | endothelial cell hey2 expression decreased amount, abnormal | s843Tg + MO1-gata1a | control | Fig. 4  from Chen et al., 2017 
 | 
    
        
            | endothelial cell notch1b expression decreased amount, abnormal | s843Tg + MO1-gata1a | control | Fig. 4  from Chen et al., 2017 
 | 
    
        
            | endothelial cell her9 expression decreased amount, abnormal | s843Tg + MO1-gata1a | control | Fig. 4  from Chen et al., 2017 
 | 
    
        
            | atrioventricular canal blood circulation process quality, abnormal | sd2Tg + MO1-gata1a | control | Fig. 2  from Heckel et al., 2015 
 | 
    
        
            | atrioventricular canal ab2-fn labeling increased amount, abnormal | ubs10Tg + MO1-gata1a | control | Fig. 5  from Steed et al., 2016 
 | 
    
        
            | atrial endocardium endothelial cell increased amount, abnormal | ubs10Tg + MO1-gata1a | control | Fig. 2  from Heckel et al., 2015 
 | 
    
        
            | dorsal aorta vascular associated smooth muscle cell mCherry expression absent, abnormal | s843Tg; uto5Tg + MO1-gata1a | control | Fig. 2  from Chen et al., 2017 
 | 
    
        
            | nucleate erythrocyte absent, abnormal | s843Tg; uto5Tg + MO1-gata1a | control | Fig. 2  from Chen et al., 2017 
 | 
    
        
            | dorsal aorta vascular associated smooth muscle cell decreased amount, abnormal | s843Tg; uto5Tg + MO1-gata1a | control | Fig. 2  from Chen et al., 2017 
 | 
    
        
            | dorsal aorta anatomical region mCherry expression absent, abnormal | s843Tg; uto5Tg + MO1-gata1a | control | Fig. 2  from Chen et al., 2017 
 | 
    
        
            | intermediate cell mass of mesoderm spi1b expression position, ameliorated | kdm1ait627/it627 + MO1-gata1a (AB) | standard conditions | Fig. 4  from Takeuchi et al., 2015 
 | 
    
        
            | blood island spi1b expression position, ameliorated | kdm1ait627/it627 + MO1-gata1a (AB) | standard conditions | Fig. 2  from Takeuchi et al., 2015 
 | 
    
        
            | nucleate erythrocyte hbae1.1 expression spatial pattern, ameliorated | p2ry12sih3/sih3 + MO1-gata1a (TU) | control | Fig. 5
                    
                    from Li et al., 2020 
 | 
    
        
            | intermediate cell mass of mesoderm spi1b expression mislocalised, abnormal | AB + MO1-etsrp + MO1-gata1a | standard conditions | Fig. 4  from Takeuchi et al., 2015 
 | 
    
        
            | blood decreased viscosity, abnormal | WT + MO1-gata1a + MO1-gata2a | standard conditions | Fig. 2  from Vermot et al., 2009 
 | 
    
        
            | blood circulating cell absent, abnormal | WT + MO1-gata1a + MO1-gata2a | standard conditions | Fig. 2  from Vermot et al., 2009 
 | 
    
        
            | atrioventricular valve morphology, abnormal | WT + MO1-gata1a + MO1-gata2a | standard conditions | Fig. 2  from Vermot et al., 2009 
 | 
    
        
            | intermediate cell mass of mesoderm spi1b expression position, ameliorated | kdm1ait627/it627 + MO1-etsrp + MO1-gata1a (AB) | standard conditions | Fig. 4  from Takeuchi et al., 2015 
 | 
    
        
            | atrioventricular canal EGFP expression decreased amount, abnormal | ig11Tg + MO1-gata1a + MO1-gata2a | control | Fig. 2  from Heckel et al., 2015 
 | 
    
        
            | caudal vein plexus size, ameliorated | y1Tg + CRISPR1-ccm2 + CRISPR2-ccm2 + CRISPR3-ccm2 + CRISPR4-ccm2 + MO1-gata1a | standard conditions | Figure 4  from Li et al., 2021 
 | 
    
        
            | dorsal aorta foxc1b expression amount, ameliorated | hu10049Tg; kca3Tg + MO1-gata1a | control | Fig. 6  from Chen et al., 2017 
 | 
    
        
            | whole organism foxc1b expression amount, ameliorated | hu10049Tg; kca3Tg + MO1-gata1a | control | Fig. 6  from Chen et al., 2017 
 |